Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on RAISIO OYJ-V SHS. We currently have 0 research reports from 0 professional analysts.
Frequency of research reports
Research reports on
RAISIO OYJ-V SHS
RAISIO OYJ-V SHS
Eyeing Up Opportunity
24 Mar 17
Produce Investment’s (PIL LN, BUY, T/P 210p) interim profits were well beneath inferred market expectations as delays in the recovery of ex-farm potato prices coincided with unusual costs associated with the company’s implementation of a new ERP system. Interim EBIT fell to £0.2m from £3.4m last year.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
N+1 Singer - Morning Song 28-03-2017
28 Mar 17
A G Barr (BAG LN) Share buybacks the main news around FY17 finals | Churchill China (CHH LN) An excellent set of 2016 results and more upgrades | Ergomed (ERGO LN) FY results show strong Services growth; Phase III Zoptrex® data ahead | Instem (INS LN) Investment to accelerate growth trajectory | Severfield (SFR LN) Strong H2 drives upgrades; CEO temporarily steps down due to ill health | Summit Therapeutics (SUMM LN) Strengthening the data package: planned extension of PhaseOut DMD | T. Clarke (CTO LN) Strong conclusion to FY16, record order book
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
Panmure Morning Note 23-03-2017
23 Mar 17
Venture Life has announced results for the full-year to 31 December 2016 and while investors got a good flavour of the FY16 performance in the January trading update, we think the performance speaks for itself. Prior to January we’d been looking for £14m top-line for the year, VLG has come in with £14.3m (+57%), adjusted EBITDA £0.8m (vs PGe adjusted EBITDA £0.6m), gross margin up, operational leverage kicking in, UltraDEX ticking along very nicely, new key hires. We consider Venture Life to be a well-positioned growth business taking advantage of a well-developed product platform, with high-quality execution. We’ll take the opportunity to revisit forecasts in due course given the recent arrival of Adrian Crockett as CFO, but our investment thesis remains and the business is looking in good shape. Buy.